Drug intelligence / Profile preview

nesbuvir

Development stage: Discontinued
Lead developer: Takeda
Modality: Small Molecules
Administration: Oral

Overview

Nesbuvir is a small molecule non-nucleoside inhibitor of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase. It binds to the palm site II pocket of the NS5B polymerase and inhibits viral genome replication. Nesbuvir demonstrated potent anti-HCV activity in vitro and in animal models, with low nanomolar inhibitory concentrations against genotype 1a and 1b replicons. The drug was investigated for use in combination therapy for hepatitis C but its clinical development was terminated during phase II trials due to safety concerns[1][2][3][4][5][7].

Other names: nesbuvir691852-58-1

Targets

NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)

Beyond the preview

Go deeper on nesbuvir.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nesbuvir.

Explore the full profile